Information updates

Novalac Allergy Infant Formula Update

Aspen Pharmacare Australia Pty Ltd took over the distribution of the Novalac infant formula range from Bayer Pharmaceuticals on 1st June 2022. 

As the distributor of Novalac Allergy, Aspen Pharmacare Australia Pty Ltd www.aspenpharma.com.au is working with the global manufacturer to ensure supply, particularly as babies who are fed Novalac Allergy Infant Formula are vulnerable patients with specialised nutrition requirements.

In recent months, global supply chains have come under strain from the impact of COVID-19 and geopolitical events such as the conflict zones in Europe. With the higher-than-average demand, stock levels of Novalac Allergy Infant Formula continue to be depleted at an accelerated pace.  

While limited availability continues, parents and carers should contact their local pharmacy to check stock levels prior to going in-store and, if the product cannot be found in-store, try online options: chemistwarehouse.com.au or priceline.com.au.

Some minor improvements to the Novalac Allergy formulation

Novalac  is constantly looking to improve the formulations to better meet the needs of babies with common feeding problems. Novalac Allergy has made improvements to some of the ingredients. The fish oil has now been replaced with 100% plant source which is rich in DHA and ARA, we have replaced glucose syrup with maltodextrin, as a result the volume per scoop and Nutrition Information Panel (NIP) has been adjusted accordingly. Please be assured that these improvements in Novalac Allergy continue to meet the nutrient requirements according to the FSANZ guidelines 2.9.5.

It is recommended that parents/carers speak to their healthcare professional who can provide medical advice about milk-substuiute products specifically for their baby if they have cow's milk (dairy) allergy, which are listed on the ASCIA website www.allergy.org.au/hp/papers/guide-for-milk-substitutes-cows-milk-allergy

This news item was issued on 24 March 2022 and updated on 10 October 2022 by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.  

Mod ASCIA Member
Donate to AIFA
go to NAC website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia